GoldenGolden
Advanced Search
Recursion Pharmaceuticals

Recursion Pharmaceuticals

Recursion Pharmaceuticals is a biotechnology and data science company based in Salt Lake City, Utah, founded in 2013, that combines biology with artificial intelligence for drug discovery. Using human cell models of diseases, Recursion captures microscopic images to build biological datasets and computational techniques identify disease-associated.

Recursion Pharmaceuticals is a biotechnology and data science company that combines biology with artificial intelligence for the discovery of drugs. Recursion takes microscopic images to build biological datasets

For diseases that can be modelled at the cellular level, Recursion uses automation in a massively parallel system to find potential treatments for disease. The initial focus was on repurposing existing drugs to treat rare diseases and has broadened to probe data for markers of inflammation, infectious disease and immunology. Recursion is using its technology to build a map of human cellular biology to increase the pace of discovering new treatments to patients.

Neural networks and other computational techniques will be used to identify changes in thousands of cellular and subcellular features associated with various biological perturbations. This approach, termed phenomics, is the large scale study of phenotypes, the study of how variations in traits are related to genetic and environmental factors. Dr. Yoshua Bengio, a pioneer of deep learning is advising on their AI strategy.

Products
REC-994

In 2018, an investigational new drug (IND) called REC-994 discovered by Recursion was FDA approved for clinical trials for treatment of cerebral cavernous malformation (CCM). CCM is a genetic disorder characterized by collections of enlarged and irregularly structured small blood vessels in the brain which alter blood flow and lead to symptoms like seizures, vision loss, hearing loss, paralysis, neurologic deficits and hemorrhagic stroke.

Funding
Funding from the Bill and Melinda gates Foundation

Recursion received funding from the Bill and Melinda Gates Foundation in spring 2018 to use its technology to discover new drugs to treat malaria.

Timeline

September 2020
Recursion Pharmaceuticals raises a $239,000,000 series D round from Advantage Capital, Baillie Gifford, Bayer, Casdin Capital, Catalio Capital Management, Data Collective, Epic Ventures, Felicis Ventures, Intermountain Ventures, Laurion Capital Management, Lux Capital Management, Mubadala, Obvious Ventures, Samsara BioCapital and Two Sigma Ventures.
July 2019
Recursion Pharmaceuticals raises a $121,000,000 series C round from Scottish Mortgage Investment Trust.
June 5, 2018
Recursion Pharmaceuticals raises a $20,500,000 venture round from Square 1 Bank.
May 7, 2018
Recursion Pharmaceuticals raises a $546,000 grant from Bill & Melinda Gates Foundation.
October 2017
Recursion Pharmaceuticals raises a $60,000,000 series B round from Data Collective.
February 7, 2017
Recursion Pharmaceuticals raises a $4,000,000 venture round from Square 1 Bank.
November 22, 2016
Recursion Pharmaceuticals raises a $2,150,000 series A round from Felicis Ventures.
October 3, 2016
Recursion Pharmaceuticals raises a $12,900,000 series A round.
December 4, 2015
Recursion Pharmaceuticals raises a $2,700,000 venture round.
February 25, 2015
Recursion Pharmaceuticals raises a $1,500,000 grant from National Institutes of Health.
Page 1 of 2

Funding rounds

SBA Awards

People

Name
Role
LinkedIn

Anne Carpenter

Advisor

Bart Robertson

Investor

Becca Parker

Employee

Ben Sukow

Employee

Blake Borgeson

Founder

brant corenson

Investor

Brian Bargh

Employee

Bril Flint

Investor

Britt McPartland

Employee

Brock Metcalf

Investor

Cedric St-Jean

Employee

Chadwick Davis

Employee

Chris Gibson

Founder

Christopher Johnson

Employee

Craig Dos Santos

Investor

CTAN - Central Texas Angel Network

Investor

Dan Graham

Investor

David Compton

Employee

Dean Li

Founder

Deena Kalai

Investor

Gary Rieschel

Investor

Gerald Lema

Investor

ian quigley

Employee

J.D. White

Employee

J.R. Kraft

Investor

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Recursion Pharmaceuticals Raises $13M To Discover New Drugs Using Artificial Intelligence - Recursion Pharmaceuticals

Recursion Pharmaceuticals

Web

Recursion Pharmaceuticals Raises $60 Million to Industrialize Drug Discovery using Artificial Intelligence - Recursion Pharmaceuticals

Recursion Pharmaceuticals

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 25, 2021
BioSpace
Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964
Amirah Al Idrus
April 16, 2021
FierceBiotech
Recursion Pharmaceuticals ramped up its IPO target from $100 million to $306 million earlier this week, but the artificial intelligence biotech is scratching that plan. Now, it's aiming to raise $374 million in its Nasdaq debut by adding 4 million more shares to the offering.
Alex Keown
April 13, 2021
BioSpace
After initially indicating it intended to raise $100 million in its Nasdaq debut, the Salt Lake City-based company will now look at bringing in approximately $306 million.
Ben Adams
April 13, 2021
FierceBiotech
Recursion Pharmaceuticals has set terms for a major $306 million IPO as the artificial intelligence biotech eyes a $3 billion valuation.
May 14, 2020
BioSpace
Recursion Enters Into Global Licensing Agreement with Takeda to Develop TAK-733 in Hereditary Cancer Syndrome - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.